The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Preliminary safety and efficacy of the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (IBR) in patients (pts) with hairy cell leukemia (HCL).
Jeffrey Alan Jones
Consultant or Advisory Role - Pharmacyclics
Research Funding - Pharmacyclics
Leslie A. Andritsos
No relevant relationships to disclose
David M Lucas
No relevant relationships to disclose
Gerard Lozanski
No relevant relationships to disclose
Terri Hutchinson
No relevant relationships to disclose
Jennifer L. Sexton
No relevant relationships to disclose
Pamela Jo Harris
No relevant relationships to disclose
Michael R. Grever
No relevant relationships to disclose